XOMA Royalty (XOMA) Expected to Announce Earnings on Tuesday

Key Points

• XOMA Royalty is set to release its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.12) per share and revenues of $9.39 million.
• In May, XOMA Royalty reported earnings of $0.06 per share, exceeding expectations, and generated revenue of $15.91 million for that quarter.
• XOMA shares fell 1.2% to $26.91, with a market capitalization of $322.03 million and a notable debt-to-equity ratio of 1.18.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $9.39 million for the quarter.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The company had revenue of $15.91 million during the quarter, compared to analyst estimates of $6.75 million. On average, analysts expect XOMA Royalty to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

XOMA Royalty Stock Up 2.6%

NASDAQ:XOMA traded up $0.66 during mid-day trading on Friday, reaching $26.50. The company's stock had a trading volume of 38,873 shares, compared to its average volume of 31,453. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $35.00. The stock has a fifty day moving average of $25.89 and a 200-day moving average of $24.22. The firm has a market capitalization of $317.21 million, a PE ratio of -23.04 and a beta of 1.00. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $104.00 price target on shares of XOMA Royalty in a report on Wednesday, May 28th. Benchmark assumed coverage on shares of XOMA Royalty in a report on Thursday, April 17th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Wall Street Zen downgraded shares of XOMA Royalty from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd.

Insider Activity

In other XOMA Royalty news, CEO Owen Hughes sold 25,637 shares of XOMA Royalty stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $25.38, for a total value of $650,667.06. Following the completion of the transaction, the chief executive officer directly owned 62,701 shares of the company's stock, valued at $1,591,351.38. The trade was a 29.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of XOMA Royalty stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the transaction, the insider directly owned 1,267,545 shares of the company's stock, valued at approximately $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.10% of the company's stock.

Hedge Funds Weigh In On XOMA Royalty

An institutional investor recently raised its position in XOMA Royalty stock. Geode Capital Management LLC increased its holdings in shares of XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) by 9.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 203,601 shares of the biotechnology company's stock after purchasing an additional 16,929 shares during the quarter. Geode Capital Management LLC owned approximately 1.70% of XOMA Royalty worth $5,132,000 at the end of the most recent quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.